The drugmaker is supporting access to NGS testing in these countries to identify lung and pancreatic cancer patients with NRG1 fusions who can join its study.
The study, slated to begin in the first half of 2021, follows recent discussion with the FDA and promising Phase II data presented at the ASH annual meeting.
The lab's involvement will increase opportunities for cancer patients in these rural states to enroll in the trial and access molecularly informed treatments.
The agency ordered Poseida to halt the trial in August after a patient died but is now allowing the company to resume the study with an amended protocol.
Researchers surveyed 171 physicians in the NCI-MATCH study to determine their tumor profiling practices and barriers to participation in future studies.
The findings demonstrate the value of multi-cohort platform trials as an option for refractory cancer patients with particularly rare genomic tumor alterations.
With an $11.8 million award, MCGI hopes to expand patient access to experimental precision oncology treatments and develop new tools for oncologists in Maine.
